www.tmepharma.com

Annual General Meeting of Shareholders

25 June 2025

TME pharma

AGENDA

1. Opening
2. Annual Accounts 2024
   a. Discussion of the annual report 2024 (discussion)
   b. Policy on additions to reserves and on dividends (discussion)
   c. Adoption of the annual accounts 2024 (voting)
   d. Release from liability of the sole member of the board of directors (voting)
   e. Release from liability of the members of the supervisory board (voting)

Voting results: all unanimously approved

3. Appointment of Diede Mink van den Ouden as sole member of the board of directors (voting)

Voting results: all unanimously approved

4. Re-appointment of Susan Coles as member of the supervisory board (voting)

Voting results: all unanimously approved

AGENDA

5. Amendment of the remuneration policy regarding the compensation structure of managing and supervisory board directors (voting)
   Voting results: unanimously approved
6. Appointment of Baker Tilly (Netherlands) N.V. as statutory auditor for the financial year 2025 (voting)
   Voting results: unanimously approved
7. Partial amendment of the articles of association in relation to the increase of the authorised share capital (voting)
   Voting results: unanimously approved
8. Partial amendment of the articles of association in relation to re-instating a transitional provision to further increase the authorised share capital (voting)
   Voting results: unanimously approved
9. Renewal of the delegation to the board of directors to issue ordinary shares and/or preference shares and to limit or exclude any pre-emptive rights in connection therewith (voting)
   Voting results: unanimously approved
10. Renewal of the delegation to the board of directors to acquire shares (voting)
    Voting results: unanimously approved
11. Close of meeting

AGENDA ITEM 2a.

Discussion of the annual report 2024 (discussion)

Pipeline Assets Complement Anti-Cancer Therapies to Enhance Treatment Efficacy

Therapy & Indication	Preclinical	Phase 1/2	Phase 2	Phase 3	Next Inflection Point	Partner/ Collaborator
NOX-A12 + Radiotherapy ± anti-VEGF **Brain cancer / Glioblastoma** Orphan Drug Designation Granted in US & EU			Phase 2 protocol approved; Fast Track awarded by FDA		Financing and initiation of randomized Ph 2	
NOX-A12 + Immunotherapy **Pancreatic Cancer**			Phase 2 protocol approved		Financing and initiation of randomized Ph 2	Scientific collaborator for Ph1/2 & Ph2 MSD

Planned external development

NOX-E36 to be Externalized and Monetized **in Ophthalmology**		Planned in Glaucoma Surgery Derisking: already tested in 175 subjects in Phase 1 & 2 in other indications				

Trial completed | Trial ongoing or in preparation | Preclinical ophthalmology animal studies completed & ongoing

All timelines subject to financing and patient recruitment

NOX-A12 (olaptesed pegol) is an injectable PEG-conjugated L-stereoisomer RNA aptamer that directly binds and neutralizes the chemokine CXCL12, preventing signaling through its two receptors CXCR4 & CXCR7. NOX-A12 also de-anchors the chemokine, destroying its gradient forming capacity.

NOX-E36 (emapticap pegol) is an injectable PEG-conjugated L-stereoisomer RNA aptamer conjugated to 40kD PEG that directly binds and neutralizes the chemokine CCL2, preventing signaling through its receptor CCR2. NOX-E36 also de-anchors the chemokine, destroying its gradient forming capacity.

AGENDA ITEM 2a.

HIGHLIGHTS 2024 & Subsequent Events

GLORIA NOX-A12 Phase 1/2 Study in First Line Brain Cancer Patients

TME Pharma advanced its lead clinical program GLORIA, a Phase 1/2 study of NOX-A12 in brain cancer (glioblastoma) patients in combination with radiotherapy ± anti-VEGF, bevacizumab. Clinical data generated to date suggest a strong signal of clinical benefit in newly diagnosed patients with glioblastoma tumors resistant to standard of care chemotherapy (MGMT unmethylated) and that are not amenable to complete surgical removal.

Clinical and regulatory highlights:

- **February 2024**: The **final median overall survival** in the GLORIA 1/2 trial for the triple combination arm reached **19.9 months**[1].
- **March 2024**: FDA cleared TME Pharma's **IND** application for a randomized Phase 2 glioblastoma trial[2].
- **April 2024**: FDA granted **Fast Track Designation** for NOX-A12 combined with radiotherapy and bevacizumab for newly diagnosed, chemotherapy-resistant glioblastoma patients with measurable tumor remaining after surgery[3].
- **April 2024: 33% of patients** receiving NOX-A12 in combination with bevacizumab and radiotherapy achieve **two-year survival**[4]**.**
- **September 2024**: Near-final efficacy data presented at the ESMO Congress showed **statistically significant survival improvement** for the triple combination (NOX-A12 + anti-VEGF + radiotherapy) compared to both standard of care and NOX-A12 + radiotherapy alone[5].

1. TME Pharma Press Release on 2 February 2024; 2. TME Pharma Press Release on 5 March 2024; 3. TME Pharma Press Release on 2 April 2024; TME Pharma Press Release on 23 April 2024; 5. Giordano (2024) ESMO Annual Meeting Oral Presentation, 15 Sept 2024 ; 6. TME Pharma Press Release on 29 January 2025

OS significantly increased for NOX-A12 + anti-VEGF + RT over standard of care and NOX-A12 + RT



Statistically significant improvement in overall survival for
NOX-A12 + anti-VEGF + RT
vs.
NOX-A12 + RT
***p*=0.021**
HR: 0.34

Statistically significant improvement in overall survival for
NOX-A12 + anti-VEGF + RT
vs.
Standard of Care (SOC)
***p*=0.003**
HR: 0.30

Source: Giordano (2024) ESMO Annual Meeting Oral Presentation, 15 Sept 2024.

AGENDA ITEM 2a.

HIGHLIGHTS 2024 & Subsequent Events

Promising New Opportunities for NOX-E36 in Ophthalmology

TME Pharma's second clinical stage asset, the CCL2 inhibitor NOX-E36, has demonstrated significant potential in addressing unmet medical need in ophthalmic diseases affected by scarring (fibrosis) and inflammation.

Preclinical highlights:

- Demonstrated anti-fibrotic activity and significant potential in ophthalmic diseases involving scarring (fibrosis) and inflammation in relevant animal models[1].
- Collaboration with the Singapore Eye Research Institute (SERI) led to preclinical data presented at ARVO 2025, showing mNOX-E36 has a more favorable safety profile than mitomycin C (MMC) and similar efficacy in reducing post-operative inflammation and scarring after glaucoma filtration surgery. Unlike MMC, mNOX-E36 does not destroy conjunctival blood vessels, potentially overcoming key toxicity limitations of current standard treatment[2].
- TME Pharma and SERI have filed patent applications for the use of NOX-E36 in glaucoma filtration surgery and other ophthalmic diseases, supporting future development through licensing or new corporate entities.
- TME Pharma is pursuing resource-efficient clinical studies, including investigator-initiated trials (IITs) funded by research institutes, while supplying the drug.

1. Kiew, S. Asian J Ophthalmol 2021 (suppl. 18).; 2. Wong (2025) ARVO Poster Presentation, 6 May 2025

AGENDA ITEM 2a.

HIGHLIGHTS 2024 & Subsequent Events

Collaboration with *aimed analytics* for AI-Driven Drug Discovery and Optimization

TME Pharma partnered with *aimed analytics* to leverage AI for accelerated drug discovery and optimization and to enable a rapid path to new or improved versions of drug candidates with new IP while reducing reliance on resource-intensive lab testing and strengthening its position for strategic transactions and partnerships.

AGENDA ITEM 2a.

- Financial Highlights
  - Cash on hand on balance sheet date of € 3.2 million (31 December 2023: € 2.2 million)
  - Net loss of € 5.7 million (compared to € 6.7 million in FY 2023), with loss from operations of € 5.3 million (FY 2023: € 5.6 million)
  - Net cash used in operating activities € 4.6 million (FY 2023: € 5.6 million)
  - Proceeds from capital raise according to the cash-flow statement of € 6.9 million (after deduction of transaction costs) during FY 2024 (FY 2023: € 4.1 million), partly used for the redemption of convertible bonds of € 1.2 million in FY 2024 (FY 2023: € 1.0 million)
  - Balance sheet total: € 3.4 million (31 December 2023: € 2.5 million)
  - Equity status: € 1.6m (31 December 2023: negative, € 0.3 million)
  - Redemption of all remaining convertible bonds in February 2024 marking the end of the convertible bond financing program

AGENDA ITEM 2a.

HIGHLIGHTS 2024

- ### Cash Position on December 31, 2024

  - On December 31, 2024, TME Pharma had cash resources of €3.2 million.
  - The Company successfully raised € 7.6 million in cash (gross) during the financial year 2024 through private placements and public offers as well as the exercise of Warrants resulting from the preferential rights issue in 2023, partly used for the redemption of 1,100 convertible bonds against the payment of € 1.2 million.

- ### Subsequent Events

  - Subsequent to 31 December 2024 and until publication of the Annual Report 2024, a total of K€ 0.1 (gross) from the exercise of ABSA Warrants resulting from the preferential rights issue in 2023.
  - Subsequent to the publication of the Annual Report in May 2025, the Company
    - announced a new strategy to facilitate ongoing efforts to finance the next clinical trial for NOX-A12 which includes further cost-cutting measures to transform the Group into a leaner organization functioning primarily on a lower-cost outsourced staffing model, significantly reducing ongoing expenses and thereby decreasing its financial needs;
    - raised € 1.7 million in cash through debt via private contractual agreements with professional European investors (at a discount to the aggregated nominal value of €2.05 million and fully repayable by the company in cash at maturity for €1.92 million, 12 months maturity, issuance of 17 million private, non-tradable warrants with an exercise price of € 0.10). This transaction was designed to limit near-term dilution potential for existing shareholders by using debt repayable in cash to provide a one-year extension to financial visibility for the company

AGENDA ITEM 2a.

Consolidated Statements of Comprehensive Loss

(in K€)	2024	2023
Other operating income	19	17
Research and development expenses	-2,296	-2,652
General and administrative expenses	-2,981	-2,989
Foreign exchange result (net)	7	9
Loss from operations	**-5,251**	**-5,615**
Finance income	32	399
Finance cost	-503	-1,518
Loss before income tax	**-5,722**	**-6,734**
Income tax	0	-2
Net loss	**-5,722**	**-6,736**
Items that may be reclassified subsequently to profit or loss		
Foreign operations – FX translation	4	-2
Total comprehensive loss	**-5,718**	**-6,738**
Net loss/total comprehensive loss attributable to:		
Owners of the Company	-5,722	-6,738
Owners of the Company	**-5,718**	**-6,738**
Loss per share in EUR per share (basic and diluted)	-0.16	-1.34

Remarks

- **Research and development expenses decreased 13%** from K€ 2,652 in FY 2023 to K€ 2,296 in FY 2024. The decrease is primarily due to the clinical trial of NOX-A12 in brain cancer nearing completion, which required lower costs while at the same time generating more mature data. The pancreatic cancer clinical trial phase 2 protocol which has been approved by the FDA in the US has not been initiated, thereby keeping ongoing costs related to this clinical trial minimal.
- **General and administrative expenses decreased** from K€ 2,989 in 2023 to K€ 2,981 in 2024. The decrease is mainly driven by lower personnel expenses as well as lower public and investor relations expenses and other expenses, partly offset by higher legal, consulting and audit fees in connection with the financing transactions in 2024.
- **Finance income** (all non-cash) decreased from K€ 399 in FY 2023 to K€ 32 in the FY 2024 as a result of ending the Atlas convertible bonds financing facility with ASO.
- **Finance cost** decreased from K€ 1,518 in the FY 2023 to K€ 503 in the FY 2024 as a result of ending the Atlas convertible bonds financing facility with ASO. Finance cost is non-cash finance cost, except for transaction costs of K€ 16 in 2024 and K€ 4 in 2023 borne by the Company in conjunction with the exercise of ABSA Warrants (in 2024) and the issuance of Atlas convertible bonds (in 2023) as well as K€ 2 in 2024 and K€ 13 in 2023 relating to interest expense for lease liabilities.

AGENDA ITEM 2a.

Consolidated Statements of Financial Position

(in K€)	2024	2023
Intangible assets	4	4
Equipment	34	35
Right-of-use asset	0	61
Financial assets	5	5
Total non-current assets	**43**	**105**
Other assets	118	141
Financial assets	5	0
Cash and cash equivalents	3,240	2,245
Total current assets	**3,363**	**2,386**
Total assets	**3,406**	**2,491**
Total equity	**1,614**	**-294**
Financial liabilities	56	1,213
Lease liabilities	0	66
Trade accounts payable	1,326	1,167
Other liabilities	410	339
Total current liabilities	**1,792**	**2,785**
Total equity and liabilities	**3,406**	**2,491**

Remarks

- The movements in total current assets from 31 December 2023 to 31 December 2024 primarily relate to an increase in cash and cash equivalents by K€ 995 from K€ 2,245 to K€ 3,240 as a result of financing activities exceeding the cash requirements for continued research and development activities.
- The change in equity from 31 December 2023 to 31 December 2024 was mainly due to the effects of capital increases resulting from financing events and the net loss incurred in 2024.
- As of 31 December 2024, the subscribed capital of the Company amounts to K€ 942 (prior year: K€ 173) and is divided into 94,185,851 ordinary shares (prior year: 17,320,845), each with a nominal value of € 0.01.
- As a result of the capital increases in 2024, additional subscribed capital of K€ 769 and additional paid-in capital of K€ 7,326 were recognized less issuance costs of K€ 779.
- Current liabilities decreased from K€ 2,785 as of 31 December 2023 by K€ 993 to K€ 1,792 as of 31 December 2024 mainly as a result of ending the Atlas convertible bonds financing with ASO (prior year: K€ 1,159). The remaining balance in financial liabilities represents the fair value of the issued and outstanding ABSA Warrants amounting to K€ 56 (prior year: €K 54).
- Trade accounts payable increased from K€ 1,167 as of 31 December 2023 to K€ 1,326 as of 31 December 2024 in the ordinary course of the business.
- Other liabilities increased from K€ 339 of 31 December 2023 to K€ 410 as of 31 December 2024 and lease liabilities decreased from K€ 66 as of 31 December 2023 to nil as of 31 December 2024 as no right-of-use assets exist.

AGENDA ITEM 2a.

Consolidated Cash-Flow Statements

(in K€)	2024	2023
Net cash used in operating activities	-4,634	-5,635
Net cash used in investing activities	-21	-19
Net cash provided by financing activities	5,660	3,266
Net change in cash and cash equivalents	**1,005**	**-2,388**
Cash at the beginning of period	**2,245**	**4,634**
Effect on movements in exchange rates on cash held	**-10**	**-1**
Cash at the end of period	**3,240**	**2,245**

Remarks

- The decrease in net cash used in operating activities from K€ 5,635 in the FY 2023 to K€ 4,634 in the FY 2024 was mainly a result of the decrease in the loss from operations, partly offset by a decrease of trade accounts payable and other liabilities.
- The increase in net cash used in investing activities from K€ 19 in the FY 2023 to K€ 21 net cash used in investing activities in the FY 2024 is due to decreased purchases of equipment and the acquisition of current financial assets.
- The increase in net cash provided by financing activities from K€ 3,266 in the FY 2023 to K€ 5,660 in the FY 2024 was mainly due to higher proceeds from the issuance of shares of the Company of K€ 6,081 (prior year: K€ 3,166) and the exercise of ABSA Warrants of K€ 1,200, (prior year: nil), partly offset by the redemption of ASO convertible bonds of K€ 1,155 (prior year: K€ 943) and no issuance of ASO convertible bonds of the Company (prior year: K€ 1,004).

AGENDA ITEM 2a.

HIGHLIGHTS 2024

- Company only financial statements 2024
  - Cash at bank and in hand on balance sheet date of € 2.4 million (prior year: € 1.6 million)
  - Net result being a loss of € 5.7 million (compared to € 6.7 million in 2023), with
    - Loss from share in results from participating interests, after taxation € 3.3 million (prior year: € 3.8 million)
    - Other result after taxation being a loss of € 2.4 million (prior year: € 2.9 million)
  - Capital raise of the Company for TME Pharma group (cash received) during 2024 is € 7.3 million (prior year: € 4.4 million), thereof through:
    - the issuance of shares in a private placement in February 2024, gross amount of € 1.48 million, cash inflow of € 1.35 million
    - the issuance of shares in a public offering and a related private placement in June 2024, gross amount of € 2.35 million, cash inflow of € 2.17 million
    - the issuance of shares upon exercise of ABSA Warrants, gross amount of € 1.20 million, cash inflow of € 1.20 million
    - the issuance of shares in a public offering in December 2024, gross amount of € 2.60 million, cash inflow of € 2.55 million.
  - Partly offset by the redemption of 1,100 ASO convertible bonds in cash amounting to € 1.2 million
  - The total equity as of 31 December 2024 amounted to K€ 1,617 compared to a negative equity of K€ 288 as of 31 December 2023.

AGENDA ITEM 2a.

SUBSEQUENT EVENTS

- Subsequent Events – refer to slide 11

- Equity position of the Company to date
  - Mainly as a result of ongoing R&D activities of the subsidiary TME Pharma AG and the May 2025 financing via a debt instrument (to be recognized as financial liability, only to be recognized as equity in case of voluntary conversion by investors), the equity position has decreased in the first months of the fiscal year 2025.
  - According to the monthly management reporting, the equity has fallen below the 50% threshold and has become negative in the second quarter of 2025.

AGENDA ITEM 2a.

- Balance Sheet of the Company

(in K€)	2024	2023
Equipment	22	15
Right-of-use assets	0	61
Financial fixed assets	0	1,221
Total fixed assets	**22**	**1,297**
Receivables due from group companies	1,189	0
Other receivables	86	98
Cash at bank and in hand	2,385	1,595
Total current assets	**3,660**	**1,693**
Total assets	**3,682**	**2,990**
Total equity	**1,617**	**-288**
Financial liabilities	56	1,213
Lease liabilities	0	66
Trade payables	924	524
Liabilities due to group companies	28	1,207
Provision for constructive obligation	717	0
Other liabilities	340	268
Total current liabilities	**2,065**	**3,278**
Total equity and liabilities	**3,682**	**2,990**

Remarks

- The Company's total fixed assets include office equipment, right-of-use assets and financial fixed assets. Total fixed assets decreased from K€ 1,297 as of 31 December 2023 to K€ 22 as of 31 December 2024 mainly as a result of decreased financial fixed assets and as a result of scheduled amortization of the right-of-use assets.
- The Company's total current assets consist of its cash at bank and in hand, receivables due from group companies and other receivables. The increase of receivables due from group companies from nil as of 31 December 2023 to K€ 1,189 as of 31 December 2024 is due invoices for management holding services.
- As of 31 December 2024, the Company's cash at bank and in hand amounted to K€ 2,385 (prior year: K€ 1,595). Other assets correspond to prepaid expenses consisting of insurance and service contracts, the Company's liquidity account as well as claims against local tax authorities for value added tax (VAT) on supplies and services received.
- The total equity as of 31 December 2024 amounted to K€ 1,617 compared to a negative equity of K€ 288 as of 31 December 2023.
- Current liabilities include financial liabilities of K€ 56 reflecting the fair value of ABSA Warrants issued and outstanding (prior year: K€ 1,213 reflecting the ASO financing (bonds payable on demand and compound derivative liability) and ABSA Warrants issued and outstanding), and further trade payables of K€ 924, other liabilities of K€ 340, liabilities due to group companies of K€ 28 (prior year: K€ 1,207) and a provision for a constructive obligation of K€ 717 (prior year: nil).

AGENDA ITEM 2a.

- Equity position of the Company

(in K€)	2024	2023
Issued capital	942	173
Share premium	84,769	77,911
Retained earnings	-78,372	-71,636
Undistributed results	-5,722	-6,736
Total equity	**1,617**	**-288**

Remarks

- As of 31 December 2024, the issued capital of the Company amounts to K€ 1,617 (prior year: K€ 173) and is divided into 94,185,851 ordinary shares (prior year: 17,320,845), each with a nominal value of € 0.01.
- In 2024, the Company issued an aggregate of 76,865,006 ordinary shares for proceeds of € 7.63 million (gross), € 7.28 million cash inflow in connection with the following financing transactions:
  - Issuance of 6,727,270 ordinary shares in a private placement in February 2024 subscribed at € 0.22, gross amount of € 1.48 million, cash inflow of € 1.35 million
  - Issuance of 13,088,158 ordinary shares in a public offering and a related private placement in June 2024 subscribed at € 0.1798, gross amount of € 2.35 million, cash inflow of € 2.17 million
  - Issuance of 5,049,578 ordinary shares upon exercise of 9,514,320 Warrants Y and 995,080 Warrants Z, gross amount of € 1.20 million, cash inflow of € 1.20 million
  - Issuance of 52,000,000 ordinary shares in a public offering in December 2024 subscribed at € 0.05, gross amount of € 2.60 million, cash inflow of € 2.55 million.
- As a result, additional issued capital of K€ 769 and share premium of K€ 7,327 were recognized less issuance costs of K€ 779.
- As a clinical stage biopharmaceutical company, the Group has incurred operating losses since inception and expects to incur operating losses in the foreseeable future due to, among other things, costs related to research funding, development of its product candidates and its preclinical programs and its administrative organization.
- Based on its new strategy and its current cash status, the Group will be required to raise further funds or conduct of a partnering deal for one of its product candidates in the second quarter of 2026 in order to execute on its plans.
- Management is actively pursuing various transaction structures in parallel to meet the Group's future cash requirements, prioritizing near-term strategic partnerships and financial transactions as well as merger/acquisition transactions that would allow further development of NOX-A12 and NOX-E36. Management is also pursuing other sources of financing including seeking additional investors, obtaining further funding from existing investors through additional funding rounds, funds from government grants, and various other back-up financing sources. The management of TME Pharma is pursuing all of these avenues with the assistance of experienced external support and with the aim of minimizing shareholders dilution wherever possible.

Strong Value Proposition Through Differentiated Pipeline Targeting the Tumor Microenvironment

MISSION

Develop **novel therapies** for **treatment of cancers** where the **Tumor Microenvironment** significantly impacts survival

NOX-A12 LEVERAGEABLE TECHNOLOGY

Dual MoA leverageable to solid tumors as combinations with:

- Radiotherapy (RT)
- Anti-vascular agents VEGF-(R)
- Immunotherapies

VERY PROMISING DATA[1]

Brain Cancer (1st line GBM) Phase 1/2 clinical trial with NOX-A12 + RT + Bevacizumab:

- **Statistically significant increase in survival vs. standard of care in chemotherapy resistant patients with residual tumor (mOS 19.9 vs 9.5 months; p=0.003) and an HR of 0.30**
- 3 of 6 patients with >99% tumor size reduction including 1 complete response
- 2 of 6 patients with survival >24 months

FOCUS ON ORPHAN CANCER INDICATIONS

Brain Cancer
(1st line GBM)
Orphan Drug Designation
Granted in US & EU, and
Fast Track designation
awarded by FDA
~$2.5 bn Addressable Market

Pancreatic Cancer
(2nd line)
~$6 bn Addressable Market

UPCOMING CATALYSTS

Financing and Initiation of Randomized Phase 2 Trial in GBM (IND open in US)

Phase 1b trial initiation of spin-out ophthalmology program for front & back-of-eye diseases

1. Giordano (2024) ESMO Annual Meeting Oral Presentation, 15 Sept 2024 and company analysis of this dataset; *TME Pharma* Press Releases from 13 July 2023, 2 February 2024, 23 April 2024

AGENDA ITEM 2b.

Policy on additions to reserves and on dividends (discussion)

AGENDA ITEM 2c.

Adoption of the annual accounts 2024 (voting)

AGENDA ITEM 2d.

Release from liability of the sole member of the board of directors (voting)

AGENDA ITEM 2e.

Release from liability of the members of the supervisory board (voting)

AGENDA ITEM 3

Appointment of Diede Mink van den Ouden as sole member of the board of directors (voting)

AGENDA ITEM 4

Re-appointment of Susan Coles as member of the supervisory board (voting)

AGENDA ITEM 5

Amendment of the remuneration policy regarding the compensation structure of managing and supervisory board directors (voting)

AGENDA ITEM 6

Appointment of Baker Tilly (Netherlands) N.V. as statutory auditor for the financial year 2025 (voting)

AGENDA ITEM 7

Partial amendment of the articles of association in relation to the increase of the authorised share capital (voting)

AGENDA ITEM 8

Partial amendment of the articles of association in relation to re-instating a transitional provision to further increase the authorised share capital (voting)

AGENDA ITEM 9

Renewal of the delegation to the board of directors to issue ordinary shares and/or preference shares and to limit or exclude any pre-emptive rights in connection therewith (voting)

AGENDA ITEM 10

Renewal of the delegation to the board of directors to acquire shares (voting)

AGENDA ITEM 11

CLOSE OF MEETING

Thank You!